Merck KGaA's EMD Serono Acquires Two of PostEra's Oral Fertility Drug Programs
- EMD Serono, Merck KGaA's US/Canada healthcare business, acquired two fertility-focused small-molecule drug discovery programs from AI-driven biotech PostEra for an undisclosed sum described as "mid-double-digit millions."
- The deal covers an oral FSHR (follicle-stimulating hormone receptor) agonist for ovarian stimulation in IVF, and an oral LHCGR (luteinizing hormone/choriogonadotropin receptor) agonist for male infertility and as an ovulation trigger.
- Both candidates are orally dosed small molecules, positioned as a potential alternative to the injectable gonadotropins that currently dominate fertility treatment.
- PostEra used its computational/AI discovery platform to design the molecules and to engineer around selectivity and liability issues; the startup had pivoted toward fertility and PMOS programs roughly a year earlier.
- The transaction acquires specific programs rather than the whole company, following PostEra's 2025 C&EN "10 Startups to Watch" recognition.
Mid-double-digit millions for two programs, not a company, is the tell: EMD Serono is buying de-risked assets à la carte rather than paying PostEra's AI-platform premium, the same capital-efficient logic behind a growing wave of biopharma bolt-ons that skip a full acquisition. Fertility is a structurally underserved category: injectable gonadotropins have dominated IVF stimulation for decades with almost no oral competition, so a credible oral FSHR/LHCGR agonist pair is a genuine convenience-and-compliance wedge, not incremental pipeline filler. For PostEra, the more interesting signal is monetization strategy: an AI-native biotech cashing out individual de-risked programs rather than building toward its own pipeline or IPO. For Merck KGaA, it's a low-risk way to reload EMD Serono's fertility franchise with next-gen oral chemistry without integration risk.